Form 4: Crinetics Pharmaceuticals COO Jeff E. Knight Acquires Stock and Options

Jeff E. Knight, Chief Operating Officer of Crinetics Pharmaceuticals, reports acquisition of common stock and stock options.

Summary

• On February 20, 2025, Jeff E. Knight, the Chief Operating Officer of Crinetics Pharmaceuticals, acquired 43,000 shares of common stock and options to purchase 65,000 shares.
• The common stock was acquired at a price of $0 per share, and the options have an exercise price of $36.86.
• The restricted stock units vest 25% annually beginning on March 15, 2026.
• The stock options vest in 48 equal monthly installments from February 20, 2025.
• Following these transactions, Knight directly owns 94,653 shares of Crinetics Pharmaceuticals common stock and options for 65,000 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The acquisition of shares and options by the COO suggests confidence, but it's a routine transaction.

Positives

• The COO's acquisition of shares and options could be interpreted as a positive signal about the company's future prospects.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. These filings are closely watched by investors for signals about management's confidence in the company's prospects.

Stakeholder Impact

• The transactions could have a minor positive impact on shareholder sentiment.

Key Dates